🕒 Monday 31 August 2026 Mon, 31 Aug 2026

Pure Foods Tasmania reports a modest revenue dip but boosts gross profit and margin in FY26, while statutory losses swell due to non-cash accounting adjustments and strategic realignment.

Thorney Opportunities Ltd swung to a $4.44 million loss before tax in FY2026, weighed down by unrealised investment losses, yet increased its final dividend and pressed on with share buybacks.

Cycliq Group Limited reported a 20.7% revenue decline to AUD 3.79 million for FY2026, but reduced its net loss by 83% to AUD 85,897, driven by disciplined cost control and strategic platform investments.

Osteopore Limited’s half-year results show an 8% revenue drop driven by currency effects, while losses widen 14% as the company invests heavily in product development and market growth.

DGL Group's FY26 results show a $5.8 million underlying loss amid investments in manufacturing and logistics capacity, with the company targeting margin improvements through better utilisation and cost control in FY27.

Eden Innovations Ltd trimmed its loss to $5 million in FY2026 while erasing bank debt and converting loans into equity, supported by property sales and capital raises.

Pengana International Equities (ASX: PIA) posted a sharp 82% plunge in net profit for FY26, triggering a strategic board reshuffle and a capital management package including a special dividend and buy-back proposal.

Peppermint Innovation Limited posted a $2.4 million net loss for FY26 as it shifted from platform development to commercial execution in the Philippines, achieving key regulatory milestones and securing strategic investment.

Infotrust Ltd (ASX: ITS) reported a 9.8% rise in FY26 revenue to $64.1 million, powered by a strategic pivot to cyber security. The company exited its Cloud segment, repaid all bank debt, and acquired Catalyst Cyber to boost federal market presence, positioning for profitable growth in FY27.

Invex Therapeutics posted a $1.35 million net loss for FY2026, driven by expanded R&D efforts and a deepening collaboration with Tessara Therapeutics targeting neurological diseases including Alzheimer’s. The company renewed its orphan drug status in Europe and restructured its board during the year.

Recce Pharmaceuticals narrowed its operating loss to AUD 15 million in FY26, progressing Phase 3 trials for its anti-infective RECCE 327 and securing key patents and commercial partnerships.

Mayfield Childcare’s HY26 results reveal a 6% revenue decline and deepening statutory loss, offset by operational improvements and strategic restructuring.

Adherium's FY2026 results show strong revenue gains from US remote patient monitoring but increased losses due to higher operating costs and commercial expansion.

Activeport Group Ltd’s FY26 results show a 36% revenue decline to $6.15 million and a net loss of $14.7 million, driven by strategic shifts towards recurring software revenue and AI infrastructure orchestration. The company launched its own national network in Australia and expanded internationally with new subsidiaries and leadership hires.

Vmoto Limited posted its strongest half-year sales ever with $35.7 million revenue and a 140% surge in unit sales, underpinned by new global partnerships and international market growth.

Oliver's Real Food swung to a statutory profit of $598k in FY2026, reversing a $2.91 million loss a year earlier, driven by store closures and cost discipline. Despite an 8% revenue drop, EBITDAI surged 36.8%, and the company kicked off FY27 with encouraging sales and earnings growth.

NOVONIX Limited posted a $24.6 million half-year loss while delivering a critical synthetic graphite sample to Panasonic and reaffirming a 2027 production start. The company raised $21.7 million to fund its North American battery materials expansion amid ongoing U.S. trade and policy developments.

Advance ZincTek posted an 11% rise in FY26 profit before tax to $2.247 million on 12.6% higher sales, driven by AI integration and US market strength. The company is set to enter residential battery manufacturing in FY27, leveraging its zinc oxide expertise.

Promisia Healthcare has cleared all material conditions for its $25 million acquisition of Chatswood Retirement Village in Christchurch, setting completion for 1 October 2026.

AF Legal Group Ltd reported a 30% surge in revenue to $35.9 million and a 354% increase in profit after tax attributable to owners in FY26, driven by strategic investments in technology and management restructuring.

Orthocell posts record FY26 revenue growth driven by expanding US and international sales of its collagen medical devices, while investing ahead in manufacturing capacity and product pipeline.

BLS Pharmaceuticals (ASX: BLS) reported a standout FY26 with revenue surging 161% to $74.2 million and net profit more than tripling to $15.4 million, driven by expanded manufacturing and major international contracts including a $50 million German supply deal.

Microba Life Sciences delivered a mixed FY26, with overall revenue slipping 5.8% to $14.76 million and a statutory loss widening 38.7% to $20.7 million. The company’s strategic pivot to core microbiome testing paid off with a 92% surge in core testing revenue and record test volumes in Australia and the UK. Despite the headline loss, underlying loss improved 11% thanks to cost cuts and AI-driven efficiencies. Microba is gearing up for the October launch of its GI Navigator diagnostic and targeting cash flow break-even on a run-rate basis in calendar 2027.

Adslot Ltd swung to a $4.2 million profit in FY2026, buoyed by a $6 million non-cash gain from deconsolidating its troubled subsidiary. The company’s restructuring efforts trimmed costs by 28%, but revenue fell 10%.